The FDA approved a new Alzheimer's drug, Kisunla, which can modestly slow cognitive decline in early disease stages, but comes with significant safety risks like brain swelling and bleeding.
Kisunla, similar to Leqembi, offers the advantage of allowing patients to stop the drug after clearing the amyloid protein target, reducing treatment costs, inconvenience, and side effects.
In clinical trials, a significant percentage of patients were able to discontinue Kisunla after clearing amyloid, with cognitive decline continuing to slow even after stopping the drug.
Lilly is assessing how long the cognitive slowing effect persists post-trial, offering hope for potential benefits even after discontinuing Kisunla.
Collection
[
|
...
]